Furthermore, D′Amato et al. [25] reported that the dual PI3K/mTOR inhibitor, PKI-587, enhances sensitivity to cetuximab in Detroit562 cells (HNSCC) having the PIK3CA mutant. This evidence concerns the gene MTOR and head and neck squamous cell carcinoma.